Physician profile
Paul Walinsky
NPI 1265455497
$2,559.87
in general payments reported to CMS, 2019-2025
17 companies · $241 in 2025
The $241 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $419 · 2020: $78.63 · 2021: $349 · 2022: $192 · 2023: $894 · 2024: $385 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,520.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,397.13 | 2021-2025 | Symplicity G3, Onyx Frontier, Corevalve Evolut R |
| Philips North America LLC | $260.16 | 2019-2024 | (Ck4) Mcot |
| Cardiovascular Systems INC. | $138.52 | 2019-2021 | |
| Edwards Lifesciences Corporation | $122.46 | 2021 | |
| Shockwave Medical, INC | $97.94 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| E.R. Squibb & Sons, L.L.C. | $92.87 | 2019-2024 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $75.04 | 2019-2025 | |
| Amgen INC. | $69.31 | 2019-2023 | Repatha |
| Chiesi USA, INC. | $64.76 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $50.42 | 2019 | |
| Janssen Pharmaceuticals, INC | $44.85 | 2020-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $44.72 | 2019 | |
| Abiomed | $34.43 | 2019 | |
| W. L. Gore & Associates, INC. | $23.16 | 2023 | Gore Cardioform Septal Occluder |
| Teleflex LLC | $17.56 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $15.38 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Walinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.